(Q35193283)

7 August 2017

1 reference

title

Hepatocellular carcinoma: are we making progress? (English)

1 reference

7 August 2017

hepatocellular carcinoma

1 reference

Andrew X Zhu

1

1 reference

7 August 2017

1 June 2003

1 reference

7 August 2017

1 reference

7 August 2017

21

1 reference

7 August 2017

418-428

1 reference

7 August 2017

3

1 reference

7 August 2017

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Genetic heterogeneity of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

HBx gene of hepatitis B virus induces liver cancer in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Suppression of apoptotic cell death by hepatitis C virus core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Transcriptional repression of p53 promoter by hepatitis C virus core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

p53 mutation in hepatocellular carcinoma after aflatoxin exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Genetic aspects of hepatocellular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Mutational hot spot in the p53 gene in human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Aberrations of p53 gene in human hepatocellular carcinoma from China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

A lack of direct role of hepatitis B virus in the activation of ras and c-myc oncogenes in human hepatocellular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

21 January 2018

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

An analysis of 412 cases of hepatocellular carcinoma at a Western center

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Liver transplantation for hepatocellular carcinoma: clinical results and future aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Cytoreductive surgery for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Clinical trials in primary hepatocellular carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

5-Fluorouracil and alpha-interferon in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

A phase II study of irinotecan in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Rising incidence of hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Point mutation, allelic loss and increased methylation of c-Ha-Ras gene in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

c-met mRNA overexpression in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Evaluation of 50 consecutive segmental hepatic resections

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Hepatic resection for hepatocellular carcinoma. An audit of 343 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Liver resection for hepatocellular carcinoma in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Experience of orthotopic liver transplantation and hepatic resection for hepatocellular carcinoma of less than 8 cm in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

A randomized trial of intrahepatic arterial infusion of 4'-epidoxorubicin with Lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Place of cryosurgery in the treatment of malignant liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

A phase 2 study of cisplatin in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Mitoxantrone in Patients Affected by Hepatocellular Carcinoma with Unfavorable Prognostic Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018233

21 January 2018

Identifiers

DOI

10.1081/CNV-120018233

1 reference

7 August 2017

1 reference

PubMed ID

12901288